5th Advances in Heart Failure 2022


SEPTEMBER, 16 – 17

5th Advances in
Heart Failure 2022

Dada a relevância dos avanços recentes na área da Insuficiência Cardíaca, a Cardiologia da Faculdade de Medicina da Universidade do Porto organiza a 5ª edição da Reunião Advances in Heart Failure, a decorrer, em formato presencial Híbrido (presencial e online) , nos dias 16 e 17 de Setembro de 2022, no Hotel Sheraton Porto.

O foco central será a divulgação, em primeira mão, dos desenvolvimentos científicos mais recentes nesta área, nomeadamente, os apresentados no Congresso Europeu de Cardiologia.

Este encontro científico ganha o seu pleno significado pela participação de um extenso corpo docente, constituído pelos peritos mais relevantes na área da Insuficiência Cardíaca, provenientes de todos os pontos do país e coadjuvado por peritos internacionais da mais elevada craveira.

Estamos certos que a troca de informação e a discussão de ideias sobre a abordagem da Insuficiência Cardíaca contribuirá, em última instância, para uma melhoria significativa dos cuidados a prestar aos doentes com Insuficiência Cardíaca no nosso país.

Sejam, por isso, bem-vindos ao Advances in Heart Failure 2022!

LOCALIZAÇÃO

Hotel Sheraton Porto
16 e 17 Setembro
2022

COMISSÃO ORGANIZADORA E CIENTÍFICA

José Silva Cardoso
Elisabete Martins
Emília Moreira

PROGRAMA


16th September 2022

  • Manhã | 09:00 – 14:00
Manhã | 09:00 – 14:00

Heart Failure with Preserved Ejection Fraction

09:00 – 09:15 Opening session
Altamiro da Costa Pereira, José Silva-Cardoso, Elisabete Martins, Emília Moreira
09:20 – 10:05 Heart Failure with preserved, normal and supra-normal LVEF
Chairs: Manuel Campelo; Luis Menezes Falcão
09:20 – 09:30 | Definitions and an approach to pathophysiology Mário Santos
09:30 – 09:40 | Diagnostic strategy Pedro Morais Sarmento
09:40 – 09:50 | Prognosis Brenda Moura
09:50 – 10:05 | Discussion Panel: Ana Oliveira Soares; Gonçalo Proença
10:10 – 10:55 Advances in HFpEF pathophysiology and new possible therapeutic targets
Chair: Mónica Mendes Pedro, Marisa Peres
10:10 – 10:20 | The relevance of pericardial fat Carlos Aguiar
10:20 – 10:30 | The central role of atrial function in HFpEF Sofia Cabral
10:30 – 10:40 | Skeletal muscle iron deficiency impact in HFpEF Rui Baptista
10:40 – 10:55 | Discussion Panel: David Roque, Manuel Vaz da Silva
10:55 – 11:15 Coffee Break
11:15 – 12:00 Industry Session Boehringer-Ingelheim / Lilly
Empagliflozin: Early and Foundational Therapy across the Heart Failure Spectrum
João Pedro Ferreira
12:05 – 12:50 Imaging in HFpEF
Chairs: Fausto Pinto, Filipe Macedo
12:05 – 12:15 | Advanced echocardiography methods Mariana Paiva
12:15 – 12:25 | Magnetic Resonance Imaging Nuno Bettencourt
12:25 – 12:35 | Other imaging techniques: When and how to use Ana G. Almeida
12:35 – 12:50 | Discussion Panel: Sofia Cabral, Regina Ribeiras
12h55-13h05 PORTHOS Study: Patient recruitment initiation  
Chair: José Silva-Cardoso
Speakers: Cristina Gavina, Rui Baptista
13:05 – 14:00 Lunch Break
  • Tarde | 14:00 – 18:40
Tarde | 14:00 – 18:40

Heart Failure with Preserved Ejection Fraction

14:00 – 14:30 ESC vs ACC/AHA Guidelines. HFpEF treatment: where do we stand in 2022?
Chairs: Cândida Fonseca, Joana Pimenta
14:00 – 14:10 | HFpEF treatment in ESC Guidelines Paulo Maia Araújo
14:10 – 14:20 | HFpEF treatment in ACC/AHA Guidelines João R. Agostinho
14:20 – 14:30 | Discussion Panel: Irene Marques; Ana Neto
14:35 – 14:45 Iron deficiency detection and treatment in HF: a survey amongst Portuguese HF experts
José Silva-Cardoso
14:50 – 15:35 HFpEF Treatment 2022: Highlights
Chairs: Elisabete Martins, Nuno Lousada
14:50 – 15:00 | MRAs Jorge Ferreira
15:00 – 15:10 | Sacubitril/Valsartan João R. Agostinho
15:10 – 15:20 | SGLT2-inhibitors John McMurray
15:20 – 15:35 | Discussion Panel: Rui Baptista; Joana Pimenta
15:35 – 15:50 Coffee Break
15:50 – 16:35 Industry Session Pfizer
Cardiac amyloidosis: Clinical practice critical issues to address in your Heart Failure patient
Chair: José Silva-Cardoso
Speakers: Omar Siddiqi; Carlos Aguiar
Welcome and Introduction José Silva-Cardoso
State of the art Omar Siddiqi
A national perspective Carlos Aguiar
Discussion: All
Take home messages: José Silva-Cardoso
16:40 – 17:25 ATTR Amyloidosis
Chairs: Alexandra Toste, Dulce Brito
16:40 – 16:50 | When and how to screen ATTR Amyloidosis in HF patients ? Xavier Resende
16:50 – 17:00 | The importance of staging and prognosis assessment in the Tafamidis era Patrícia Rodrigues
17:00 – 17:10 | Aortic stenosis and ATTR amyloidosis: how to manage the frequent duo in elderly patients? Elisabete Martins
17:10 – 17:25 | Discussion Panel: Mariana Vasconcelos; Ana Rita Almeida
17:30 – 18:15 Management of Hypertrophic Cardiomyopathy: What’s new?
Chairs: Hugo Madeira; Nuno Cardim 
17:30 – 17:40 | Cardiembolic risk: Do we need more scoring or longer monitoring? Alexandra Sousa
17:40 – 17:50 | Mavacamten in HF stage C patients Luis Lopes
17:50 – 18:00 |ICD recommendation: a critical appraisal of the American and European Guidelines Sérgio Barra
18:00 – 18:15 | Discussion Panel: Luis Adão; António Fiarresga
18:20 – 18:40 Mini Industry Session Abbott
The role of remote monitoring in patients with HFpEP: Evidence from CardioMems experience
Speaker: Tiago Pereira da Silva

17th September 2022

  • Manhã | 09:00 – 14:15
Manhã | 09:00 – 14:15

Heart Failure with Preserved Ejection Fraction

09:00-09:20 Cell Therapy in Heart Failure
Chair: Lino Gonçalves
Speaker: Diana Nascimento
09:25 – 10:10 Industry Session Vifor Pharma
Serum potassium control during RAASi optimization – from scientific evidence to clinical practice
Chair: Cândida Fonseca
Speaker: José Silva-Cardoso, Irene Marques
Welcome and introduction Cândida Fonseca
Hyperkalemia as a limiting factor for neurohormonal blockade/modulation in clinical practice José Silva-Cardoso
Clinical case: Serum potassium control for RAASi optimization in HF Irene Marques
Discussion: All
Conclusions and adjourn: Cândida Fonseca
10:15 – 10:35 The c-GMP pathway: the lunar side of Heart Failure
Chair: Armando Mansilha
Speaker: José Silva-Cardoso
10:35 – 10:50 Coffee Break
10:50 – 11:35 Industry Session Servier
Sacubitril/Valsartan: From Guidelines to Clinical Practice
Chair: José Silva-Cardoso
Speakers: Carlos Aguiar, Alexandra Sousa, Filipa Almeida
Guidelines AHA 2022 Carlos Aguiar
Critical clinical practice issues: challenges and opportunities (eg HF – NYHA class II) and challenges
(Hk, hypotension, comorbidities; drug costs vs hospitalization costs; balance for NHS
Alexandra Sousa, Filipa Almeida
11:40 – 12:25 New approaches to acute and worsening Heart Failure
Chairs: Aurora Andrade, Adelino Leite-Moreira
11:40 – 11:50 | Early ambulatory detection and intervention (The CHAMPION trial) (champion strategy; telemonitorização e
opt da Re congestiva) Roberto Pinto
11:50 – 12:00 | Early in-hospital intervention: converting a threat into an opportunity (The TRANSITION, EMPULSE
and AFFIRM-AHF Trials) Cristina Gavina
12:00 – 12:10 | Early post-discharge intervention: the vulnerable phase intervention (The VICTORIA Trial) Sara Gonçalves
12:10 – 12:25 | The Galactic-HF: a new perspective for worsening Heart Failure Cândida Fonseca
Discussion Panel: Marta Braga; Inês Araújo
12:30 – 13:15 Industry Session Bayer
The Cardiorenal Future Starts Now: Vericiguat and Finerenone
Chair: José Silva-Cardoso
Welcome and introduction José Silva Cardoso
The Bayer Commitment to Cardio-Renal Research Isabel Fonseca Santos
The concept of Worsening Heart Failure José Silva-Cardoso
Vericiguat; a novel Heart Failure therapeutic pathway Gilles Dekeulenaer
Discussion: all
13:15 – 14:15 Lunch Break
  • Tarde | 14:15 – 18:25
Tarde | 14:15 – 18:25

Heart Failure with Preserved Ejection Fraction

14:15 – 15:00 Industry Session Novartis
Can we change the outlook for patients with HFrEF?
Chair: José Silva-Cardoso
Speakers: José Silva-Cardoso, Marta Nogueira
15:05 – 15:50 Rhythm control in HF
Chairs: João Morais; Jorge Ferreira
15:05 – 15:15 | Atrial fibrillation rhythm control: New insights from EAST-HFNET.AF and RAFT-HF João Primo
15:15 – 15:25 | Ventricular Tachycardia Ablation: PARTITA trial – a Game changer? Pedro Adragão
15:25 – 15:35 | The 2022 ESC Ventricular Arrhythmias and SCD Guidelines: echoes from the ESC Congress Ana Lebreiro
15:35 – 15:50 | Discussion Panel: Filipa Almeida; Marta Nogueira
15:55 – 16:40 Industry Session Abbott
Moving Forward in HF Management: recent advances and evidence in breaktrough devices
Chair: Paulo Pinho
Speakers: Marta Tavares da Silva; Carlos Aguiar
Mitraclip Marta Tavares da Silva
Tendyne Marta Tavares da Silva
HeartMate3 Carlos Aguiar
16:40 – 16:55 Coffee Break
16:55 – 17:40 Advanced HF – Heart Transplantation. Overcoming donor organs shortage  
Chairs: Victor Gil, Elisabete Martins
16:55 – 17:05 | Improving organ procurement organization in Portugal Fátima Franco
17:05 – 17:15 | Organ donation after circulatory death Sandra Amorim
17:15 – 17:25 |Transgenic organs and Xenotransplantation: the future? Carlos Aguiar
17:25 – 17:40 | Discussion Panel: Rui Ferreira; Doroteia Silva
17:45 – 18:15 Heart Failure: Beyond Ejection Fraction
Chair: José Silva-Cardoso
Speaker: Javed Butler
18:20 – 18:25 Meeting Closure
José Silva-Cardoso; Elisabete Martins; Emília Moreira

MAIS INFORMAÇÕES


O foco central será a divulgação, em primeira mão, dos desenvolvimentos científicos mais
recentes nesta área, nomeadamente, os apresentados no Congresso Europeu de Cardiologia.

Este encontro científico ganha o seu pleno significado pela participação de um extenso
corpo docente, constituído pelos peritos mais relevantes na área da Insuficiência Cardíaca,
provenientes de todos os pontos do país e coadjuvado por peritos internacionais da mais
elevada craveira.

Estamos certos que a troca de informação e a discussão de ideias sobre a abordagem da
Insuficiência Cardíaca contribuirá, em última instância, para uma melhoria significativa dos
cuidados a prestar aos doentes com Insuficiência Cardíaca no nosso país.

SPONSORS

Aspect image

Aspect image
Aspect image
Aspect image
Aspect image
Aspect image
Aspect image
Aspect image
Aspect image
Aspect image


ADVANCES IN HEART FAILURE







ADVANCES IN HEART FAILURE






@ Advances in Heart Failure 2023. Todos os direitos reservados.







@ Advance in Heart Failure 2023. Todos os direitos reservados.